右美托嘧啶的临床应用进展分析

Analysis of Clinical Application Progress of Dexmedetopyrimidine

右美托嘧啶(DEX)是临床中应用率较高的α2肾上腺素受体激动剂,其对α2受体与α1受体的激动比例是1620:1,药物分布的半衰期为6 min,药物消除的半衰期为2 h,经由肝脏代谢.其发挥镇静与镇痛作用的主要依据是α2-AR,可调节去甲肾上腺素(NE)释放,兴奋神经元,确保血管活性药物的临床疗效.DEX用于临床治疗的效果较佳,可发挥镇痛、抑制交感神经活性与镇静等治疗功效,且不会导致呼吸抑制等反应.其于1999年被允许用于重症监护病房(ICU)的临床治疗中.目前,其主要用于术前镇静、术中麻醉与术后镇痛等临床实践中,具有较为广阔的应用前景.研究中详细论述DEX的临床应用进展,以指导其科学使用.

Dextropyrimidine (DEX) is α2-adrenoceptor agonists with high clinical application rate. Its activation ratio of α2-receptor to α1-receptor is 1620:1. The half-life of drug distribution is 6 minutes, and the half-life of drug elimination is 2 hours, which is metabolized by liver. Its sedative and analgesic effects are mainly based on α2-AR, which can regulate the release of norepinephrine (NE), excite neurons and ensure the clinical efficacy of vasoactive drugs. DEX has better effect in clinical treatment. It can exert the therapeutic effects of analgesia, inhibition of sympathetic nerve activity and sedation, and does not lead to respiratory depression and other reactions. It was allowed to be used in the clinical treatment of ICU (Intensive Care Unit) in 1999. At present, it is mainly used in clinical practice such as preoperative sedation, intraoperative anesthesia and postoperative analgesia, and has a broad application prospects. The progress of clinical application of DEX will be discussed in detail in order to guide its scientific use.